A meta-analysis of 4247 patients in 20 published articles concluded that the immunohistochemical loss of SMAD4 predicted a poor overall survival in both Asian and Caucasian patients with pancreatic cancer, but did not correlate with tumor size, differentiation, or lymph node metastasis [91]. The gene discussed is SMAD4; the disease is pancreatic neoplasm.